As of the latest Form 4 filed Jul 7, 2026.
What Incyte Corporation insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 39 most recent filings for INCY.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-02 | Mayes Patrick A EVP & Chief Scientific Officer | FTax | −350.00 | $116.86 | $40.9K | No | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Tray Thomas Principal Accounting Officer | FTax | −477.00 | $116.86 | $55.7K | No | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Stein Steven H CMO & Head of Late-Stage Dev. | FTax | −2.18K | $116.86 | $254K | No | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Meury William Chief Executive Officer | FTax | −4.78K | $116.86 | $558K | No | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | Clancy Paul J Director | AAward | +252.00 | $113.36 | $28.6K | No | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | BAKER BROS. ADVISORS LP Director | AAward | +400.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | BAKER BROS. ADVISORS LP, Director | AAward | +400.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-02 | 2026-06-30 | HARRIGAN EDMUND Director | AAward | +255.00 | $113.36 | $28.9K | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | High Katherine A Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | Clancy Paul J Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | FOUSE JACQUALYN A Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | BIENAIME JEAN JACQUES Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | BRAWLEY OTIS W Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | BAKER BROS. ADVISORS LP Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | BAKER BROS. ADVISORS LP, Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-10 | 2026-06-08 | HARRIGAN EDMUND Director | AAward | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-08 | 2026-06-04 | Tray Thomas Principal Accounting Officer | SSale | −2.64K | $100.00 | $264K | Yes (planned) | Form 4 ↗ |
| 2026-06-08 | 2026-06-04 | Tray Thomas, Principal Accounting Officer | MExercise | +2.64K | $83.83 | $221K | Yes (planned) | Form 4 ↗ |
| 2026-06-03 | 2026-06-01 | CAGNONI PABLO J President, Global Head of R&D | FTax | −25.5K | $95.59 | $2.43M | No | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | Tray Thomas Principal Accounting Officer | SSale | −2.05K | $97.35 | $200K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | BIENAIME JEAN JACQUES Director | FTax | −13.1K | $97.10 | $1.27M | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-26 | BIENAIME JEAN JACQUES, Director | MExercise | +15.0K | $84.53 | $1.27M | Yes (planned) | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Clancy Paul J Director | SSale | −15.0K | $94.93 | $1.42M | Yes (planned) | Form 4 ↗ |
| 2026-05-21 | 2026-05-19 | Clancy Paul J, Director | MExercise | +15.0K | $84.53 | $1.27M | Yes (planned) | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | BAKER BROS. ADVISORS LP Director | MExercise | +15.0K | $84.53 | $1.27M | No | Form 4 ↗ |
| 2026-05-11 | 2026-05-08 | BAKER BROS. ADVISORS LP, Director | MExercise | +15.0K | $84.53 | $1.27M | No | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Upadhyay Suketu EVP & Chief Financial Officer | AAward | +26.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | CAGNONI PABLO J President, Global Head of R&D | SSale | −18.7K | $96.50 | $1.80M | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | CAGNONI PABLO J, President, Global Head of R&D | MExercise | +12.6K | $71.93 | $906K | Yes (planned) | Form 4 ↗ |
| 2026-04-21 | 2026-04-17 | CAGNONI PABLO J, President, Global Head of R&D | MExercise | +6.08K | $64.25 | $390K | Yes (planned) | Form 4 ↗ |
| 2026-04-17 | 2026-04-15 | Stein Steven H CMO & Head of Late-Stage Dev. | AAward | +39.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-17 | 2026-04-15 | Meury William Chief Executive Officer | MExercise | +125K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-17 | 2026-04-15 | CAGNONI PABLO J President, Global Head of R&D | AAward | +27.9K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-26 | 2026-03-25 | Trotta Matteo EVP, GM, Dermatology US | FTax | −537.00 | $92.23 | $49.5K | No | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | CAGNONI PABLO J President, R&D | SSale | −18.7K | $94.24 | $1.76M | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | CAGNONI PABLO J, President, R&D | MExercise | +11.5K | $64.25 | $739K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | CAGNONI PABLO J, President, R&D | MExercise | +7.17K | $61.18 | $438K | Yes (planned) | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Heeson Lee EVP, Head of Incyte Intl | FTax | −111.00 | $102.67 | $11.4K | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Morrissey Michael James EVP, Head of Tech. Operations | FTax | −185.00 | $102.67 | $19.0K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also INCY’s full analysis or the market-wide insider trading feed. The tabs above jump to INCY’s other SEC data.
Source: SEC Form 4 filings for INCY, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.